Scinai Immunotherapeutics Ltd. current report, Q1 FY2018

Full document

Business Context and Reporting Period

This Form 6-K filing by BiondVax Pharmaceuticals Ltd. (not Scinai Immunotherapeutics Ltd.) covers the month of March 2018, with the report dated March 21, 2018. The filing serves as an update to previous announcements regarding a partnership with a European contract research organization (CRO) to conduct a Phase 3 clinical trial planned for the 2018/19 flu season.

Key Financial Metrics

The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on the execution of a contractual agreement rather than financial performance reporting.

Material Changes

On March 15, 2018, the Company and the CRO executed a master service agreement and a work order, formalizing a letter of intent announced in January 2018 and the CRO appointment announced in March 2018. Key terms include:

  • Effective Date: March 8, 2018.
  • Duration: Five years or longer if work orders remain in effect.
  • First Work Order: Governs the European clinical trial with a scheduled duration of 32.5 months.
  • Termination: The Company may terminate the agreement or work order with 45 days' notice or in the event of a material breach.
  • Compensation: The Company will pay remuneration and reimburse costs incurred by the CRO.

Guidance, Outlook, and Risks

Management commentary indicates the trial is scheduled to begin prior to the 2018/19 flu season. The filing does not provide specific financial guidance, risk factors, or contingencies beyond the standard termination clauses within the service agreement.

Investor Verification Checklist

  • Verify the identity of the specific European CRO appointed for the Phase 3 trial.
  • Confirm the total estimated cost of the 32.5-month work order and the Company's current cash runway to fund these obligations.
  • Review the specific clinical endpoints and patient enrollment targets for the 2018/19 flu season trial.
  • Check for any subsequent filings regarding the trial's initiation date or regulatory approvals in Europe.